The sterility testing market is expected to expand steadily as the pharmaceutical, biotechnology, and medical device industries continue to grow and adopt stricter quality control standards. Increasing production of biologics, vaccines, cell and gene therapies, and injectable drugs is driving demand for reliable sterility testing methods to ensure product safety. Regulatory agencies such as the FDA and EMA are enforcing more rigorous guidelines, prompting companies to invest in advanced testing platforms, including rapid microbiological methods and automated systems. The rising number of contract manufacturing and testing organizations also contributes to market growth, as companies outsource sterility testing to reduce operational complexity. Additionally, technological advancements—such as membrane filtration improvements, ATP bioluminescence assays, and real-time microbial detection—are increasing testing accuracy and reducing turnaround times. Emerging markets with expanding pharmaceutical manufacturing capabilities offer significant growth potential. Overall, the sterility testing market is poised for sustained expansion driven by innovation, regulatory compliance needs, and rising global drug production.